Top-Line Results from Clinical Trial Show Capsadyn™ Does Not Burn
March 15, 2024–Chorda Pharma today announced positive top-line results from a clinical trial for studying the skin burning characteristics of Capsadyn™ (0.25%), an over-the-counter topical analgesic formulated as a proprietary capsaicin-based cream with a concentration of 0.25%. Capsadyn™’s burning properties were statistically equivalent to the placebo cream (p = 0.32). On the other hand, Zostrix®…
